Nelson N Stone

Summary

Country: USA

Publications

  1. ncbi Factors influencing urinary symptoms 10 years after permanent prostate seed implantation
    Nelson N Stone
    Department of Urology, NNS and Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 187:117-23. 2012
  2. ncbi Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial
    Hiroyuki Konaka
    Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Japan
    BMC Cancer 12:110. 2012
  3. ncbi Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Int J Radiat Oncol Biol Phys 76:355-60. 2010
  4. ncbi Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
    Nelson N Stone
    Departments of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 183:634-9. 2010
  5. ncbi Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Urology 66:119-23. 2005
  6. ncbi The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 177:925-8. 2007
  7. ncbi Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Urology 69:338-42. 2007
  8. ncbi Patterns of local failure following prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    J Urol 177:1759-63; duscussion 1763-4. 2007
  9. ncbi Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 185:495-500. 2011
  10. ncbi Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007

Collaborators

Detail Information

Publications67

  1. ncbi Factors influencing urinary symptoms 10 years after permanent prostate seed implantation
    Nelson N Stone
    Department of Urology, NNS and Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 187:117-23. 2012
    ..We investigated the factors that influenced urinary symptoms in the first 10 years after prostate brachytherapy...
  2. ncbi Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial
    Hiroyuki Konaka
    Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Japan
    BMC Cancer 12:110. 2012
    ..A prospective study on the efficacy and safety of trimodality treatment consisting of HT, external beam radiation therapy (EBRT), and brachytherapy (BT) for high-risk prostate cancer (PCa) is strongly required...
  3. ncbi Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Int J Radiat Oncol Biol Phys 76:355-60. 2010
    ..To determine factors that influence local control and systemic relapse in patients undergoing permanent prostate brachytherapy (PPB)...
  4. ncbi Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
    Nelson N Stone
    Departments of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 183:634-9. 2010
    ..We evaluated the effect of neoadjuvant hormonal therapy on urinary function in men with a prostate volume of 50 cc or greater undergoing prostate brachytherapy...
  5. ncbi Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Urology 66:119-23. 2005
    ..All have been associated with some degree of pulmonary seed migration, and no studies have clearly investigated a means of decreasing this problem...
  6. ncbi The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 177:925-8. 2007
    ..We describe the effects of prostate brachytherapy with or without hormonal therapy, or external beam irradiation on gland volume...
  7. ncbi Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    Urology 69:338-42. 2007
    ..To define the long-term morbidity in patients with prostate cancer who underwent iodine-125 brachytherapy...
  8. ncbi Patterns of local failure following prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    J Urol 177:1759-63; duscussion 1763-4. 2007
    ..We describe biopsy results in patients with prostate cancer treated with brachytherapy...
  9. ncbi Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 185:495-500. 2011
    ..We describe how treatment factors influence biochemical freedom from failure, local control, freedom from metastasis and cause specific survival in patients treated with prostate brachytherapy...
  10. ncbi Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007
    ..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group...
  11. ncbi Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, New York, USA
    J Urol 173:803-7. 2005
    ..We determined the 10-year biochemical and local control results for I prostate brachytherapy in men followed a minimum of 4 years...
  12. ncbi Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY 10075, USA
    Brachytherapy 9:114-8. 2010
    ..To investigate the morbidity of higher radiation doses in prostate cancer patients...
  13. ncbi Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy
    Alice Y Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 75:16-22. 2009
    ..To evaluate the influence of patient- and treatment-related factors on freedom from biochemical failure (FFbF) in patients with intermediate-risk prostate cancer...
  14. ncbi A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 68:1410-6. 2007
    ..To examine whether possession of genetic alterations in the ATM (ataxia telangiectasia) gene is associated with rectal bleeding in a dose-dependent and volume-dependent manner...
  15. ncbi (125)I monotherapy using D90 implant doses of 180 Gy or greater
    Johnny Kao
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 70:96-101. 2008
    ..The purpose of this study was to characterize the oncologic results and toxicity profile of patients treated with (125)I implants using the dose delivered to 90% of the gland from the dose-volume histogram (D90) of greater than 144 Gy...
  16. ncbi Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 64:527-33. 2006
    ..To analyze the effect of biologically effective dose (BED) values on prostate-specific antigen (PSA) failure and posttreatment biopsy...
  17. ncbi Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer
    Ryan J Burri
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    Int J Radiat Oncol Biol Phys 77:1315-21. 2010
    ..To evaluate retrospectively the biochemical outcomes of young men treated with low-dose-rate brachytherapy for prostate cancer...
  18. ncbi Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer
    Ryan J Burri
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Radiat Res 170:49-59. 2008
    ..002). These results suggest that SNPs in the SOD2, XRCC1 and XRCC3 genes are associated with the development of late radiation injury in patients treated with radiation therapy for prostate adenocarcinoma...
  19. ncbi Distant and local recurrence in patients with biochemical failure after prostate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, 1184 5th Avenue, New York, NY 10025, USA
    Brachytherapy 7:217-22. 2008
    ..To analyze the patterns of failure after the brachytherapy management of localized prostate cancer...
  20. ncbi Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:341-6. 2009
    ..To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED)...
  21. ncbi Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation
    Lucille N Lee
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 52:444-52. 2002
    ..CONCLUSION: In this retrospective review, HTx improved outcome in intermediate- to high-risk prostate cancer patients treated with brachytherapy. HTx was the most important prognostic factor in the univariate and multivariate analyses...
  22. ncbi Long-term potency preservation following brachytherapy for prostate cancer
    Kurt M Snyder
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 110:221-5. 2012
    ....
  23. ncbi Combined modality treatment in the management of high-risk prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Box 1236, 1184 5th Avenue, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 59:1352-9. 2004
    ....
  24. ncbi Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer
    Ryan J Burri
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 77:1338-44. 2010
    ..To describe long-term outcomes and toxicity after salvage brachytherapy (BT) for local failure after initial radiotherapy for prostate cancer...
  25. ncbi TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy
    Christopher A Peters
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 70:752-9. 2008
    ..To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy...
  26. ncbi Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 66:389-94. 2006
    ....
  27. ncbi PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure
    Eric C Ko
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 83:600-7. 2012
    ..5 ng/mL following brachytherapy is associated with decreased PSA failure and/or distant metastasis...
  28. ncbi Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 2:17-25. 2003
    ..To compare the results of intraoperative dosimetry with those of CT-based postimplant dosimetry in patients undergoing prostate seed implantation...
  29. ncbi Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure
    Richard G Stock
    Departments of Radiation Oncology Urology, Mount Sinai School of Medicine, New York, NY, USA
    BJU Int 110:1257-61. 2012
    ..This study provides information on the prognostic significance of primary Gleason pattern in the brachytherapy management of prostate cancer. Study Type - Prognosis (case series) Level of Evidence 4..
  30. ncbi Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 2:32-9. 2003
    ..This study prospectively assessed the long-term effects of (125)I prostate brachytherapy on urinary morbidity...
  31. ncbi What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Brachytherapy 1:83-9. 2002
    ..To define the optimal dose for 125I prostate implants by correlating post implant CT dosimetry findings with urinary symptoms, biochemical failure, and posttreatment biopsies...
  32. ncbi Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy
    Richard G Stock
    Departments of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 104:1631-6. 2009
    ..To assess the outcomes for patients with Gleason score 8-10 prostate cancer treated with brachytherapy, external beam radiotherapy (EBRT) and hormonal therapy (HT)...
  33. ncbi Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai Hospital, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 74:753-8. 2009
    ..To analyze the prognosis and outcomes of patients who remain free of biochemical failure during the first 5 years after treatment...
  34. ncbi Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Brachytherapy 1:2-10. 2002
    ..To maximize control while minimizing toxicity, doses of 65-70 Gy of 103Pd should be used when 59.4 Gy of three-dimensional EBRT is delivered. Longer follow-up will be needed to further substantiate these findings...
  35. ncbi Urinary symptom flare following I-125 prostate brachytherapy
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 56:1085-92. 2003
    ..There appears to be no statistically significant association between a late exacerbation in urinary symptoms and clinical or implant parameters...
  36. ncbi Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 60:648-53. 2004
    ....
  37. ncbi Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 56:448-53. 2003
    ..The impact of PSA bounce on PSA failure was also explored...
  38. ncbi Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy
    Todd J Carpenter
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 10:261-8. 2011
    ..To evaluate the efficacy of multimodality therapy consisting of hormone therapy (HT), brachytherapy (BT), and external beam radiotherapy (EBRT) in extraprostatic prostate cancer and identify factors with predictive value...
  39. ncbi Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS
    Timothy M Zagar
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 6:26-33. 2007
    ..This study is to compare the Mount Sinai Erectile Function Score (MSEFS), our brachytherapy program's physician-assigned scale, with patients' independently completed International Index of Erectile Function-5 (IIEF-5)...
  40. ncbi There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy
    Amy N Solan
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Int J Radiat Oncol Biol Phys 73:1468-74. 2009
    ..We evaluated the relationship between the onset of erectile dysfunction and dose to the penile bulb and neurovascular bundles (NVBs) after real-time ultrasound-guided prostate brachytherapy...
  41. ncbi Disease-specific survival following the brachytherapy management of prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai Hospital, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 64:810-6. 2006
    ..To determine disease-specific survival (DSS) and associated predictive factors after prostate brachytherapy...
  42. ncbi C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    BJU Int 95:961-2. 2005
    ....
  43. ncbi Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer
    Christopher A Peters
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:24-9. 2009
    ..To determine the impact familial prostate cancer has on prognosis in men treated with brachytherapy for clinically localized prostate cancer...
  44. ncbi Prostate gland motion and deformation caused by needle placement during brachytherapy
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 1:154-60. 2002
    ..To determine the extent of edge and gland position changes caused by needle insertion in patients undergoing prostate brachytherapy...
  45. ncbi ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 61:196-202. 2005
    ....
  46. ncbi Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai Medical Center, Bronx, New York, NY 10029, USA
    BJU Int 96:328-9. 2005
    ....
  47. ncbi Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, 1 Gastave Levy Place, New York, NY 10029, USA
    Urol Clin North Am 30:351-62. 2003
    ..Well-controlled, randomized studies are needed. In the meantime, the clinician will have to rely on the available published data...
  48. ncbi Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease
    Christopher A Peters
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 66:424-9. 2006
    ..We report on the follow-up of 24 patients with a prior history of inflammatory bowel disease (IBD) treated with brachytherapy for early-stage prostate cancer...
  49. ncbi Importance of post-implant dosimetry in permanent prostate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Box 1236, 1184 5th Avenue, New York, NY 10025, USA
    Eur Urol 41:434-9. 2002
    ..The technique, results and correlation with clinical outcomes will be presented...
  50. ncbi Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer
    Alice Y Ho
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 6:38-43. 2007
    ..Dose-volume histogram (DVH) analysis of the SV was performed in patients with biopsy-positive SV who received implantation of the SV and prostate...
  51. ncbi Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up
    Jamie A Cesaretti
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 100:362-7. 2007
    ..To evaluate the effect of low-dose rate prostate brachytherapy on the sexual health of men with > or = 7 years of prospective evaluation and optimum sexual function before treatment...
  52. ncbi Biopsy and implantation of the seminal vesicles
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, New York, NY, USA
    Brachytherapy 11:334-40. 2012
    ..To describe the technique and outcomes of seminal vesicle biopsy (SVB) and permanent implantation in patients with T3b prostate cancer...
  53. ncbi Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer
    Steven Lehrer
    Department of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, NY, USA
    Urol Oncol 7:73-6. 2002
    ..Further studies of AUA symptom score and outcome would be worthwhile. If AUA symptom score is a predictor of outcome that is independent of t stage, AUA score might be clinically valuable in disease management...
  54. ncbi Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation
    Richard G Stock
    Department of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, New York 10025, USA
    J Urol 183:546-50. 2010
    ..We assessed the impact of androgen suppressive therapy on biochemical failure in patients with intermediate risk prostate cancer treated with brachytherapy and external beam irradiation...
  55. ncbi Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy
    Steven Lehrer
    Department of Radiation Oncology and Urology, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Urol 173:79-81. 2005
    ..In the current study we analyzed the relationship of prostate size and prostate specific antigen (PSA) failure in men undergoing brachytherapy for localized prostate cancer...
  56. ncbi Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    Urol Oncol 21:101-4. 2003
    ..0, P = 0.14). Also, there is an association of APC mutations with thyroid cancer. In this study, we measured triiodothyronine (t3) levels in Ashkenazi Jewish prostate cancer patients, with and without the I1307K mutation of the APC gene...
  57. ncbi Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine and Veterans Affairs Medical Center, The Bronx, New York, USA
    J Urol 168:2431-3. 2002
    ..Triiodothyronine may be such a biomarker. Also, new prostate cancer and BPH therapies may be directed toward inhibiting the mitogenic effects of triiodothyronine...
  58. ncbi Brachytherapy for the treatment of prostate cancer
    Jamie A Cesaretti
    Department of Radiation Oncology, The Mount Sinai School of Medicine, James J Peters VA Hospital, New York, NY, USA
    Cancer J 13:302-12. 2007
    ....
  59. ncbi Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Mount Sinai Hospital, 1184 5th Avenue, New York, NY 10029, USA
    Urol Clin North Am 37:83-96, Table of Contents. 2010
    ..This article focuses on the development of a real-time ultrasound-guided implant technique, the importance of radiation dose, trimodality treatment of high-risk disease, long-term treatment outcomes, and treatment-associated morbidity...
  60. ncbi Increased serum insulin associated with increased risk of prostate cancer recurrence
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Prostate 50:1-3. 2002
    ..Also, new prostate cancer therapies might be directed toward inhibiting the mitogenic effects of insulin...
  61. ncbi Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment
    Anna C Ferrari
    New York University Cancer Institute, New York University Medical School, 160 E 34th St, 8th Floor, New York, NY 10016, USA
    J Clin Oncol 24:3081-8. 2006
    ..More discriminatory staging procedures are needed to identify occult micrometastases that spawn BCR...
  62. ncbi Long-term Outcomes and Toxicity in Patients Treated With Brachytherapy for Prostate Adenocarcinoma Younger Than 60 Years of Age at Treatment With Minimum 10 Years of Follow-up
    Michael Buckstein
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY
    Urology 81:364-9. 2013
    ..To report the outcomes and late toxicities in younger patients with long-term follow-up treated with brachytherapy with or without external beam radiotherapy for prostate adenocarcinoma...
  63. ncbi Permanent seed implantation for localized adenocarcinoma of the prostate
    Nelson N Stone
    Department of Urology, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Curr Urol Rep 3:201-6. 2002
    ..Advances in technology, such as intraoperative dosimetry, will continue to make brachytherapy an attractive treatment option for men with localized prostate cancer...
  64. ncbi Influence of prostate volume on dosimetry results in real-time 125I seed implantation
    Lee K McNeely
    Department of Radiation Oncology, Boulder Community Hospital, Boulder, CO, USA
    Int J Radiat Oncol Biol Phys 58:292-9. 2004
    ..Patients with glands >40 cm3 were 25% likely to have a D90 result >180 Gy and were at only 3% risk of a D90 <140 Gy. These patients may benefit from intraoperative dosimetry or a reduction in implant activity...
  65. ncbi Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation
    Steven Lehrer
    Department of Radiation Oncology, Mount Sinai Medical Center, New York 10029, USA
    BJU Int 98:979-81. 2006
    ..g. terazosin, combined with sildenafil, might be of benefit. Also, patients with a high IPSS before brachytherapy can be warned that they have a greater risk of flare and ED...
  66. ncbi Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer
    Steven Lehrer
    J Natl Cancer Inst 94:1893; author reply 1893-4. 2002
  67. ncbi Morbidity after brachytherapy for prostate adenocarcinoma
    Thomas M Pisansky
    Mayo Clin Proc 79:946-7; author reply 947-9. 2004